Dupilumab‐associated head and neck dermatitis: Rapid response with abrocitinib treatment

Abstract

Abstract Development or exacerbation of head and neck dermatitis (HN‐D) in association with dupilumab has been reported. Severity of HN‐D varies, and may persist even with discontinuation of dupilumab. Development or exacerbation of HN‐D is not yet completely understood, and various hypotheses have been made about the possible underlying pathophysiology. To date, there is no established treatment for HN‐D in association with dupilumab. We report 2 cases of HN‐D occurring following dupilumab treatment, with significant improvement of HN‐D following treatment with abrocitinib.